KRAS and colorectal carcinoma: The microsatellite-stable, BRAF wild-type, and CIMP-negative CRC subgroups showed longer disease-free survival when treated with 5-FU-based chemotherapy (log-rank test: p = 0.003 for the KRAS mutation subgroup and p < 0.001 for the KRAS wild-type subgroup) [47].